Works by Haanen, J. B. A. G.

Results: 17

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Published in:

British Journal of Cancer, 2025, v. 132, n. 12, p. 1124, doi. 10.1038/s41416-025-03021-5

By:

Bloem, M.;
de Meza, M. M.;
van den Eertwegh, A. J. M.;
Aarts, M. J. B.;
van den Berkmortel, F. W. P. J.;
Blank, C. U.;
Blokx, W. A. M.;
Boers-Sonderen, M. J.;
Bonenkamp, J. J.;
Boreel, C. D. M.;
de Groot, J. W. B.;
Haanen, J. B. A. G.;
Hospers, G. A. P.;
Kapiteijn, E.;
van Not, O. J.;
Piersma, D.;
Rikhof, B.;
Stevense-den Boer, A. M.;
van der Veldt, A. A. M.;
Vreugdenhil, G.

Publication type:

Article

HLA Class-II-restricted<em> Mycobacterium leprae</em>-reactive T-Cell Clones from Leprosy Patients Established with a Minimal Requirement for Autologous Mononuclear Cells.

Published in:

Scandinavian Journal of Immunology, 1986, v. 23, n. 1, p. 101, doi. 10.1111/j.1365-3083.1986.tb01947.x

By:

Haanen, J. B. A. G.;
Ottenhoff, T. H. M.;
Voordouw, A.;
Elferink, B. G.;
Klatser, P. R.;
Spits, H.;
De Vries, R. R. P.

Publication type:

Article

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.

Published in:

Cancer Immunology, Immunotherapy, 2005, v. 54, n. 9, p. 926, doi. 10.1007/s00262-005-0677-2

By:

Kerst, J. M.;
Bex, A.;
Mallo, H.;
Dewit, L.;
Haanen, J. B. A. G.;
Boogerd, W.;
Teertstra, H. J.;
de Gast, G. C.

Publication type:

Article

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care.

Published in:

Journal of Cancer Survivorship, 2025, v. 19, n. 1, p. 109, doi. 10.1007/s11764-023-01452-8

By:

Egeler, M. D.;
Boomstra, E.;
Rohaan, M. W.;
Van den Heuvel, N. M. J.;
Fraterman, I.;
Delfos, M.;
van de Poll-Franse, L. V.;
Borch, T. H.;
Svane, I. M.;
Haanen, J. B. A. G.;
Retèl, V. P.;
Boekhout, A. H.

Publication type:

Article

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

Published in:

2016

By:

De Groot, S.;
Sleijfer, S.;
Redekop, W. K.;
Oosterwijk, E.;
Haanen, J. B. A. G.;
Kiemeney, L. A. L. M.;
Uyl-de Groot, C. A.

Publication type:

journal article

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

Published in:

BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10457-y

By:

Borgers, J. S. W.;
Burgers, F. H.;
Terveer, E. M.;
van Leerdam, M. E.;
Korse, C. M.;
Kessels, R.;
Flohil, C. C.;
Blank, C. U.;
Schumacher, T. N.;
van Dijk, M.;
Henderickx, J. G. E.;
Keller, J. J.;
Verspaget, H. W.;
Kuijper, E. J.;
Haanen, J. B. A. G.

Publication type:

Article

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 447, doi. 10.1007/s00280-023-04517-8

By:

Groenland, Stefanie L.;
Janssen, J. M.;
Nijenhuis, C. M.;
de Vries, N.;
Rosing, H.;
Wilgenhof, S.;
van Thienen, J. V.;
Haanen, J. B. A. G.;
Blank, C. U.;
Beijnen, J. H.;
Huitema, A. D. R.;
Steeghs, N.

Publication type:

Article

Azathioprine-induced pure red-cell aplasia.

Published in:

Nephrology Dialysis Transplantation, 1996, v. 11, n. 7, p. 1371, doi. 10.1093/oxfordjournals.ndt.a027561

By:

Pruijt, J. F. M.;
Haanen, J. B. A. G.;
Hollander, A. A. M. J.;
den Ottolander, G. J.

Publication type:

Article

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Published in:

Journal of Clinical Pharmacology, 2017, v. 57, n. 1, p. 125, doi. 10.1002/jcph.788

By:

Nijenhuis, C. M.;
Huitema, A. D. R.;
Blank, C.;
Haanen, J. B. A. G.;
Thienen, J. V.;
Rosing, H.;
Schellens, J. H. M.;
Beijnen, J. H.

Publication type:

Article

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma F. A. Vyth-Dreese et al. NK T cells in renal cell carcinoma.

Published in:

Clinical & Experimental Immunology, 2010, v. 162, n. 3, p. 447, doi. 10.1111/j.1365-2249.2010.04274.x

By:

Vyth-Dreese, F. A.;
Sein, J.;
Van De Kasteele, W.;
Dellemijn, T. A. M.;
Van Den Bogaard, C.;
Nooijen, W. J.;
De Gast, G. C.;
Haanen, J. B. A. G.;
Bex, A.

Publication type:

Article

Cryoablation and immunotherapy: an overview of evidence on its synergy.

Published in:

Insights into Imaging, 2019, v. 10, n. 1, p. 1, doi. 10.1186/s13244-019-0727-5

By:

Aarts, B. M.;
Klompenhouwer, E. G.;
Rice, S. L.;
Imani, F.;
Baetens, T.;
Bex, A.;
Horenblas, S.;
Kok, M.;
Haanen, J. B. A. G.;
Beets-Tan, R. G. H.;
Gómez, F. M.

Publication type:

Article

Cryoablation and immunotherapy: an overview of evidence on its synergy.

Published in:

Insights into Imaging, 2019, v. 10, n. 1, p. 1, doi. 10.1186/s13244-019-0727-5

By:

Aarts, B. M.;
Klompenhouwer, E. G.;
Rice, S. L.;
Imani, F.;
Baetens, T.;
Bex, A.;
Horenblas, S.;
Kok, M.;
Haanen, J. B. A. G.;
Beets-Tan, R. G. H.;
Gómez, F. M.

Publication type:

Article

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Published in:

British Journal of Cancer, 2014, v. 110, n. 10, p. 2441, doi. 10.1038/bjc.2014.194

By:

Lankheet, N A G;
Kloth, J S L;
Gadellaa-van Hooijdonk, C G M;
Cirkel, G A;
Mathijssen, R H J;
Lolkema, M P J K;
Schellens, J H M;
Voest, E E;
Sleijfer, S;
de Jonge, M J A;
Haanen, J B A G;
Beijnen, J H;
Huitema, A D R;
Steeghs, N

Publication type:

Article

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Published in:

2010

By:

van der Veldt, A. A. M.;
Meijerink, M. R.;
van den Eertwegh, A. J. M.;
Haanen, J. B. A. G.;
Boven, E.

Publication type:

journal article

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

Published in:

2009

By:

van der Veldt, A. A. M.;
Boven, E.;
van den Eertwegh, A. J. M.;
Haanen, J. B. A. G.

Publication type:

Letter

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

Published in:

2008

By:

van der Veldt, A A M;
Boven, E;
Helgason, H H;
van Wouwe, M;
Berkhof, J;
de Gast, G;
Mallo, H;
Tillier, C N;
van den Eertwegh, A J M;
Haanen, J B A G

Publication type:

journal article

Targeting dendritic cells with antigen via dendritic cell-associated promoters.

Published in:

Cancer Gene Therapy, 2012, v. 19, n. 5, p. 303, doi. 10.1038/cgt.2012.2

By:

Moulin, V;
Morgan, M E;
Eleveld-Trancikova, D;
Haanen, J B A G;
Wielders, E;
Looman, M W G;
Janssen, R A J;
Figdor, C G;
Jansen, B J H;
Adema, G J

Publication type:

Article